The CARM1 epigenetic enzyme inhibits cross-presenting dendritic cell function in cancer immunity
Science · 2026
DOI: 10.1126/science.aea1200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, 2026. Verfasst von Xixi Zhang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA. Hauptthemen laut MEDLINE: Antigen Presentation, Cross-Priming, Dendritic Cells, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: National Institutes of Health, National Science Foundation graduate research fellowships program.
Abstract (Originalsprache)
The cancer-immunity cycle requires cross-presenting type I conventional dendritic cells (cDC1s) that induce T cell–mediated immunity, but therapeutic strategies for enhancing intratumoral cDC1 function are currently inadequate. We found the epigenetic enzyme CARM1 (coactivator-associated arginine methyltransferase 1) to be a selective negative regulator of cancer antigen presentation by cDC1s but not cDC2s. Inactivation of the Carm1 gene promoted cDC1 antigen cross-presentation, activation, and accumulation in tumors, and a CARM1 inhibitor enhanced cDC1-mediated priming of T cells by means of a cancer neoantigen vaccine. CARM1 inhibition increased chromatin accessibility at BATF3-Jun and RelA sites that are critical for cDC1 function and activation. Transforming growth factor–β regulated Carm1 expression, which suggests that CARM1 inactivation enhanced intratumoral cDC1 function without altering cDC1 homeostasis. These studies identify CARM1 as a potential therapeutic target for enhancing the antitumor function of mouse and human cDC1s.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Department of Immunology, Harvard Medical School, Boston, MA, USA.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Broad Institute of Harvard and MIT, Cambridge, MA, USA.
- Systems, Synthetic, and Quantitative Biology Graduate Program, Harvard University, Cambridge, MA, USA.
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
ORCID-Profile: Xixi Zhang, Sherin Xirenayi, Ye Zhao, Wen Wang, Shawn Kang, Chi Zhang, Graham L Barlow, Jason Pyrdol, Jae-Won Cho, Kun Huang, Xiaohan Ning, Martin Hemberg, Guo-Cheng Yuan, Eliezer M Van Allen, David J Mooney, Kai W Wucherpfennig
Förderung
- National Institutes of Health
- National Science Foundation graduate research fellowships program
Zitieren
APA
Zhang, X., Xirenayi, S., Zhao, Y., Wang, W., Han, Y., Sobral, M., Kang, S., Zhang, C., Barlow, G. L., Pyrdol, J., Cho, J. W., Huang, K., Ning, X., Hemberg, M., Yuan, G. C., Van Allen, E. M., Mooney, D. J., & Wucherpfennig, K. W. (2026). The CARM1 epigenetic enzyme inhibits cross-presenting dendritic cell function in cancer immunity. Science. https://doi.org/10.1126/science.aea1200
Vancouver
Zhang X, Xirenayi S, Zhao Y, Wang W, Han Y, Sobral M, et al. The CARM1 epigenetic enzyme inhibits cross-presenting dendritic cell function in cancer immunity. Science. 2026. doi:10.1126/science.aea1200
BibTeX
@article{Zhang2026,
author = {Zhang, Xixi and Xirenayi, Sherin and Zhao, Ye and Wang, Wen and Han, Yuyang and Sobral, Miguel and Kang, Shawn and Zhang, Chi and Barlow, Graham L and Pyrdol, Jason and Cho, Jae-Won and Huang, Kun and Ning, Xiaohan and Hemberg, Martin and Yuan, Guo-Cheng and Van Allen, Eliezer M and Mooney, David J and Wucherpfennig, Kai W},
title = {The CARM1 epigenetic enzyme inhibits cross-presenting dendritic cell function in cancer immunity},
journal = {Science},
year = {2026},
doi = {10.1126/science.aea1200}
}
EUVIMED